Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP and PET-Oriented RT in Low-Risk DLBCL
NCT03364439Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2012
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Started Jan 2012; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03364439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364439.